Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?

References

• Badiyan SN, Ferraro DJ, Yaddanapudi S, Drzymala RE, Lee AY, Silver SA, Dyk P, DeWees T, Simpson JR, Rich KM, Robinson CG. (2013). Impact of time of day on outcomes after stereotactic radiosurgery for non–small cell lung cancer brain metastases. Cancer. 119:3563–9.
   PubMed Web of Science ®Google Scholar
• Becciolini A, Balzi M, Potten CS. (1995). Radiation effects on proliferation and differentiation in the rat small intestine. In Potten CS, eds., Radiation and Gut. Wiley Online Library, Hoboken, NJ., pp. 85–143.
   Google Scholar
• Bernard S, Bernard BČ, Lévi F, Herzel H. (2010). Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol. 6:e1000712.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C. (2009). Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: A prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys. 73:166–72.
   PubMed Web of Science ®Google Scholar
• Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. (2002). Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 94:1121–30.
   PubMed Web of Science ®Google Scholar
• Buchi KN, Moore JG, Hrushesky WJ, Southern RB, Rubin NH. (1991). Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 101:410–5.
   PubMed Web of Science ®Google Scholar
• Chan S, Rowbottom L, McDonald R, Zhang L, Bjarnason GA, Tsao M, Danjoux C, Barnes E, Lam H, Popovic M, DeAngelis C. (2016). Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases? Ann Palliat Med. 5(4):267–279.
   Google Scholar
• Chen D, Cheng J, Yang K, Ma Y, Yang F. (2013). Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets Ther. 6:1507.
   PubMed Web of Science ®Google Scholar
• Clayton F, Tessnow KA, Fang JC, Holden JA, Moore JG. (2002). Circadian variation of Topoisomerase II-à in human rectal crypt epithelium: Implications for reduction of toxicity of chemotherapy. Mod Pathol. 15:1191–6.
   PubMed Web of Science ®Google Scholar
• Dhadda AS, Zaitoun AM, Bessell EM. (2009). Regression of rectal cancer with radiotherapy with or without concurrent capecitabine—optimising the timing of surgical resection. Clin Oncol. 21:23–31.
   Web of Science ®Google Scholar
• Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. (2000). Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 355:1745–50.
   PubMed Web of Science ®Google Scholar
• Endlich B, Radford IR, Forrester HB, Dewey WC. (2000). Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. Radiat Res. 153:36–48.
   PubMed Web of Science ®Google Scholar
• Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. (2003). Chronotherapy for cancer. Biomed Pharmacother. 57:92–5.
   Web of Science ®Google Scholar
• Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F. (1994). Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infusional Chemother. 5:148–52.
   Google Scholar
• Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. (1999). Influence of the interval between preoperative radiation therapy and surgery on down-staging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol. 17:2396.
   PubMed Web of Science ®Google Scholar
• Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. (2011). Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci. 108:18790–5.
   PubMed Web of Science ®Google Scholar
• Gaddameedhi S, Selby CP, Kemp MG, Ye R, Sancar A. (2015). The circadian clock controls sunburn apoptosis and erythema in mouse skin. J Invest Dermatol. 135:1119–27.
   PubMed Web of Science ®Google Scholar
• Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W. (2003). Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 21:3808–13.
   PubMed Web of Science ®Google Scholar
• Garufi C, Vanni B, Aschelter AM, Zappalà AR, Bria E, Nisticò C, Sperduti I, Cognetti F, Terzoli E. (2006). Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur J Cancer. 42:608–16.
   PubMed Web of Science ®Google Scholar
• Geyfman M, Kumar V, Liu Q, Ruiz R, Gordon W, Espitia F, Cam E, Millar SE, Smyth P, Ihler A, Takahashi JS. (2012). Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci. 109:11758–63.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 24:3562–9.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M. (2012). Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis. Ann Oncol. 23:3110–6.
   PubMed Web of Science ®Google Scholar
• Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S, Pant MC, Verma NS. (2009). Oral mucositis in morning vs. evening irradiated patients: A randomised prospective study. Int J Radiat Biol. 85:504–9.
   PubMed Web of Science ®Google Scholar
• Granda TG, Filipski E, D’Attino RM, Vrignaud P, Anjo A, Bissery MC, Lévi F. (2001). Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res. 61: 1996–2001.
   PubMed Web of Science ®Google Scholar
• Guo P, Wang H, Jiang R, Wang Z. (2015). The clinical effect study on malignant tumors with chronoradiotherapy. Biol Rhythm Res. 46:249–55.
   Web of Science ®Google Scholar
• Haus E, Halberg F, Loken MK, Kim YS. (1974). Circadian rhythmometry of mammalian radiosensitivity. Space Radiat Biol. 435–74.
   Google Scholar
• Haus E. (2002). Chronobiology of the mammalian response to ionizing radiation potential applications in oncology. Chronobiol Int. 19:77–100.
   PubMed Web of Science ®Google Scholar
• Hendry JH. (1975). Diurnal variations in radiosensitivity of mouse intestine. Br J Radiol. 48:312–4.
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E. (2012). Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 13:579–88.
   PubMed Web of Science ®Google Scholar
• Hsu FM, Hou WH, Huang CY, Wang CC, Tsai CL, Tsai YC, Yu HJ, Pu YS, Cheng JC. (2016). Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiol Int. 33:210–9.
   PubMed Web of Science ®Google Scholar
• Huang XL, Fu CJ, Bu RF. (2011). Role of circadian clocks in the development and therapeutics of cancer. J Int Med Res. 39:2061–6.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yu Q, Liu Y, Zhu Z, Wang L, Wang H, Li K. (2016). Efficacy and safety of chronomodulated chemotherapy for patients with metastatic colorectal cancer: A systematic review and meta‐analysis. Asia‐Pacific J Clin Oncol. 13(2):171–178.
   Google Scholar
• Joiner M, Van Der Kogel A. (2009). Basic clinical radiobiology. 4th edition. Boca Raton, FL. Taylor & Francis Group.
   Google Scholar
• Kaminski A, Joseph D, Elsaleh H. (2007). Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. Aust Radiol. 51:283–8.
   PubMedGoogle Scholar
• Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS. (2005). Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 62:97–103.
   PubMed Web of Science ®Google Scholar
• Kirichenko AV, Rich TA. (1999). Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys. 44:659–64.
   PubMed Web of Science ®Google Scholar
• Klevecz RR, Shymko RM, Blumenfeld D, Braly PS. (1987). Circadian gating of S phase in human ovarian cancer. Cancer Res. 47:6267–71.
   PubMed Web of Science ®Google Scholar
• Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Delivery Rev. 59:1015–35.
   PubMed Web of Science ®Google Scholar
• Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer treatments. Ann Rev Pharmacol Toxicol. 50:377–421.
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:681–6.
   PubMed Web of Science ®Google Scholar
• Lévi F. (2006). Chronotherapeutics: The relevance of timing in cancer therapy. Cancer Causes Control. 17:611–21.
   PubMed Web of Science ®Google Scholar
• Lévi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Adam R. (1994). Chronomodulated versus fixed-infusion—rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (Leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst. 86:1608–17.
   PubMed Web of Science ®Google Scholar
• Li J, Chen R, Ji M, Zou SL, Zhu LN. (2015). Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: A randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 76:651–5.
   PubMed Web of Science ®Google Scholar
• Liao C, Li J, Bin Q, Cao Y, Gao F. (2010). Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: A meta-analysis of five randomized controlled trials. Int J Colorectal Dis. 25:343–50.
   PubMed Web of Science ®Google Scholar
• Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Qiu F, Mo HY, Mai HQ, Guo X, Xian LJ, Hong MH. (2013). Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 32:502.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M. (2010). Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 11:835–44.
   PubMed Web of Science ®Google Scholar
• Martin ST, Heneghan HM, Winter DC. (2012). Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 99:918–28.
   PubMed Web of Science ®Google Scholar
• Miglietta L, Bruzzone M, Ghione G, Pepe A, Marenghi C, Ragni N, Boccardo F. (2001). Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. Tumori. 88:204–8.
   Web of Science ®Google Scholar
• Mormont MC, Levi F. (1997). Circadian‐system alterations during cancer processes: A review. Int J Cancer. 70:241–7.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Quirke P. (2008). What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 26:303–12.
   PubMed Web of Science ®Google Scholar
• Noh JM, Choi DH, Park H, Huh SJ, Park W, Seol SW, Jeong BK, Nam SJ, Lee JE, Kil WH. (2014). Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. J Radiat Res. 55:553–8.
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. (1994). Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Eng J Med. 331:502–7.
   PubMed Web of Science ®Google Scholar
• Palombo P, Moreno-Villanueva M, Mangerich A. (2015). Day and night variations in the repair of ionizing-radiation-induced DNA damage in mouse splenocytes. DNA Rep. 28:37–47.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Sgroi G, Sarti E, Barni S. (2016). Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: A meta-analysis of published studies. Ann Surg. 263:458–64.
   Google Scholar
• Plikus MV, Vollmers C, de la Cruz D, Chaix A, Ramos R, Panda S, Chuong CM. (2013). Local circadian clock gates cell cycle progression of transient amplifying cells during regenerative hair cycling. Proc Natl Acad Sci. 110:E2106–15.
   Google Scholar
• Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. (2004). Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 3:235–42.13.
   PubMedGoogle Scholar
• Rahn DA, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O’Quigley JM, Rich T. (2011). Gamma knife radiosurgery for brain metastasis of non-small cell lung cancer: Is there a difference in outcome between morning and afternoon treatment? Cancer. 117:414–20.
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR. (2002). Coordination of circadian timing in mammals. Nature. 418:935–41.
   PubMed Web of Science ®Google Scholar
• Roh MS, Yothers GA, O’Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry JC. (2011). The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. InASCO Annual Meeting Proceedings May 20 (Vol. 29, No. 15_suppl, p. 3503).
   Google Scholar
• Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O’donoghue DP, Moriarty M, Fennelly D, Sheahan K. (2005). Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 47:141–6.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Eng J Med. 351:1731–40.
   PubMed Web of Science ®Google Scholar
• Scheving LE, Feures RJ, Tsai TH, Scheving LA. (1994). Experimental background for cancer chronotherapy. Circadian Cancer Ther. 19–40.
   Google Scholar
• Shukla P, Gupta D, Bisht SS, Pant MC, Bhatt ML, Gupta R, Srivastava K, Gupta S, Dhawan A, Mishra D, Negi MP. (2010). Circadian variation in radiation‐induced intestinal mucositis in patients with cervical carcinoma. Cancer. 116:2031–5.
   PubMed Web of Science ®Google Scholar
• Sloothaak DA, Geijsen DE, Van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, Tanis PJ. (2013). Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 100:933–9.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Lote K, Sothern RB, Laerum OD. (1993). DNA synthesis and ploidy in non-Hodgkin’s lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res. 53:3129–38.
   PubMed Web of Science ®Google Scholar
• Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC, Lévi F. (1998). Docetaxel chronopharmacology in mice. Cancer Res. 58:3896–904.
   PubMed Web of Science ®Google Scholar
• Verma Y, Chauhan AK, Singh H, Sabharwal R, Bharti M, Kaur P. (2014) Chronomodulated chemotherapy and concomitant radiotherapy for the management of locally advanced head and neck squamous cell carcinoma. Int J Pharm Sci Res. 5:1015.
   Google Scholar
• Zhang Y, Chen X, Ren P, Su Z, Cao H, Zhou J, Zou X, Fu S, Lin S, Fan J, Yang B. (2013). Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 87:356–62.
   PubMed Web of Science ®Google Scholar